Adrian Elliott
@elliottad.bsky.social
Heart Foundation Future Leader Fellow, Centre for Heart Rhythm Disorders | University of Adelaide
Arrhythmias | Heart Failure | Cardiology | Exercise |
Arrhythmias | Heart Failure | Cardiology | Exercise |
Reposted by Adrian Elliott
Fantastic presentation from Mina Chung on the results of the TRIM-AF study.
RFM +/- Metformin had benefit in symptoms but no benefit on AF burden.
RFM +/- Metformin had benefit in symptoms but no benefit on AF burden.
November 18, 2024 at 4:35 PM
Fantastic presentation from Mina Chung on the results of the TRIM-AF study.
RFM +/- Metformin had benefit in symptoms but no benefit on AF burden.
RFM +/- Metformin had benefit in symptoms but no benefit on AF burden.
Reposted by Adrian Elliott
Congrats to Rajeev Pathak, @prashsanders.bsky.social and team on the ARREST-AF RCT.
Incredibly informative data - adjective comprehensive risk factor optimisation significantly improved post ablation AF freedom.
We now have RCT evidence supporting RFM as a foundation and pillar of AF management.
Incredibly informative data - adjective comprehensive risk factor optimisation significantly improved post ablation AF freedom.
We now have RCT evidence supporting RFM as a foundation and pillar of AF management.
November 18, 2024 at 8:09 PM
Congrats to Rajeev Pathak, @prashsanders.bsky.social and team on the ARREST-AF RCT.
Incredibly informative data - adjective comprehensive risk factor optimisation significantly improved post ablation AF freedom.
We now have RCT evidence supporting RFM as a foundation and pillar of AF management.
Incredibly informative data - adjective comprehensive risk factor optimisation significantly improved post ablation AF freedom.
We now have RCT evidence supporting RFM as a foundation and pillar of AF management.
Reposted by Adrian Elliott
#Tirzepatide for Obesity Treatment & Diabetes Prevention
SURMOUNT-1 Trial
✅ Reduced progression to T2DM by 93%
#CardioSky #EndoSky #MedSky #NEJM
www.nejm.org/doi/full/10....
SURMOUNT-1 Trial
✅ Reduced progression to T2DM by 93%
#CardioSky #EndoSky #MedSky #NEJM
www.nejm.org/doi/full/10....
Tirzepatide for Obesity Treatment and Diabetes Prevention | NEJM
Obesity is chronic disease and causal precursor to myriad other conditions, including
type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown
to provide substantial a...
www.nejm.org
November 14, 2024 at 3:44 AM
#Tirzepatide for Obesity Treatment & Diabetes Prevention
SURMOUNT-1 Trial
✅ Reduced progression to T2DM by 93%
#CardioSky #EndoSky #MedSky #NEJM
www.nejm.org/doi/full/10....
SURMOUNT-1 Trial
✅ Reduced progression to T2DM by 93%
#CardioSky #EndoSky #MedSky #NEJM
www.nejm.org/doi/full/10....
